Emera Incorporated(EMA)Earnings, Financials & Key RatiosEmera Incorporated (EMA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's dividend coverage is inconsistent, with an OCF-to-dividend ratio that dropped to 0.6 in 2025Q2, signaling potential risks to shareholder distributions amidst ongoing cash flow deficits.
Emera Incorporated (EMA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Emera Incorporated (EMA) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.98vs $0.87+13.7% | $2.0Bvs $1.7B+16.1% |
| Q1 2026 | Feb 23, 2026 | $0.40vs $0.42-3.9% | $1.5Bvs $1.1B+28.5% |
| Q4 2025 | Nov 7, 2025 | $0.64vs $0.44+45.7% | $2.1Bvs $1.7B+24.1% |
| Q3 2025 | Aug 7, 2025 | $0.57vs $0.47+22.5% | $2.0Bvs $1.8B+9.7% |
Recent stock market news and headlines for Emera Incorporated (EMA)
Johnson and Johnson presents new IMAAVYÂ (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained dise
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positi
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) acro
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
Key metrics vs top competitors for Emera Incorporated (EMA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $53.19 | $16.12B | 22.37 | 15.31% | 13.11% | 8.16% | 2.54% | |
| $14.62 | $10.43B | 11.60 | -0.37% | 10.72% | 13.55% | — | |
| $115.19 | $52.73B | 29.46 | 8.98% | 13.56% | 10.57% | — | |
| $36.39 | $27.38B | 22.74 | 6.85% | 13.09% | 8.32% | — | |
| $87.12 | $20.08B | 23.80 | 1.65% | 14.71% | 8.65% | — | |
| $108.61 | $13.16B | 21.51 | 4.2% | 11.99% | 9.27% | — |
Emera Incorporated (EMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when EMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Emera Incorporated (EMA) stock FAQ — growth, dividends, profitability & financials explained
Emera Incorporated (EMA) reported $8.59B in revenue for fiscal year 2025. This represents a 942% increase from $824.6M in 1999.
Emera Incorporated (EMA) grew revenue by 15.3% over the past year. This is strong growth.
Yes, Emera Incorporated (EMA) is profitable, generating $1.07B in net income for fiscal year 2025 (13.1% net margin).
Yes, Emera Incorporated (EMA) pays a dividend with a yield of 2.54%. This makes it attractive for income-focused investors.
Emera Incorporated (EMA) has a return on equity (ROE) of 8.2%. This is below average, suggesting room for improvement.
Emera Incorporated (EMA) had negative free cash flow of $1.81B in fiscal year 2025, likely due to heavy capital investments.
Emera Incorporated (EMA) has a dividend payout ratio of 53%. This suggests the dividend is well-covered and sustainable.
